Search | Clinical Trials Finder

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Glaucoma
Interventions: Travoprost 0.004%/timolol maleate 0.5% fixed combination; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions: Latanoprost with Pilocarpine vs Timolol or Cosopt; Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 50 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Slingerlands, New York

Conditions: Infantile Hemangioma, Very Low Birth Weight Infants
Interventions: topical 0.5% Timolol maleate, Control (placebo) group; Drug
Lead sponsor: Alice K. Gong; Other
Eligibility: Up to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Open Angle
Interventions: brimonidine, timolol; Drug
Lead sponsor: Chicago Center for Vision Research; Other
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 12
States / cities: Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more

Conditions: Glaucoma
Interventions: Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Infantile Hemangioma
Interventions: 0.25% Timolol Maleate Gel Forming Solution, 0.5% Timolol Maleate Gel Forming Solution; Drug
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: Up to 84 Days
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 9 more

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Scleral Buckling
Interventions: Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops; Drug
Lead sponsor: Jason Hsu, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Open Angle, Ocular Hypertension
Interventions: Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Bourbonnais, Illinois • Charlotte, North Carolina

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: timolol hemihydrate, timolol maleate; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: timolol maleate 0.5%, dorzolamide/timolol maleate fixed combination, latanoprost 0.005%, placebo; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 2
States / cities: Lakeland, Florida • Bourbonnais, Illinois

Conditions: Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome, Pseudoexfoliation Glaucoma
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Newark, New Jersey

Search by objective public record fields.

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

The International Collaborative Exfoliation Syndrome Treatment Study

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Safety and IOP-Lowering Effects of WB007

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Cosopt Versus Xalatan

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects